Advertisement
Product › Details
ADCT-401 (ADC Therapeutics / MedImmune)
Next higher product group | antibody-drug conjugate (ADC) | |
Status | 2014-05-19 development pc planned | |
Organisation | MedImmune (biologics division of AstraZeneca) | |
Group | AstraZeneca (Group) | |
Organisation 2 | ADC Therapeutics S.à.r.l. (ADCT) | |
Today | ADC Therapeutics S.A. (NYSE: ADCT) | |
Group | ADC Therapeutics (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antibody-drug conjugate (ADC)
- [1] TORL BioTherapeutics, LLC. (4/10/24). "Press Release: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline". Los Angeles, CA....
- [2] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [3] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
- [4] Ipsen S.A.. (4/2/24). "Press Release: Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting solid tumors". Paris & San Francisco, CA....
- [5] Tubulis GmbH. (3/14/24). "Press Release: Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline". Munich....
- [6] Tubulis GmbH. (3/5/24). "Press Release: Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024". Munich....
- [7] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
- [8] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
- [9] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
- [10] Simris Group AB. (12/20/23). "Press Release: Simris Biologics Signs Material Transfer Agreement with Pre-clinical Biotech Company to Develop Linker-Payloads"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top